Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non–small cell lung cancer, in the first randomized trial of immunotherapy timing. The results provide prospective support for aligning treatment with circadian biology as a simple way to improve cancer outcomes.
A 2026 study studied this question.